Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of PIK3CA Allows In Vitro Growth but Not In Vivo Progression of KRAS Mutant Lung Adenocarcinoma in a Syngeneic Orthotopic Implantation Model.

Cells - 12 Mar 2026

Booth Abigail L, Caso Giuseppe, Rosati Barbara, Jiang Ya-Ping, Zong Wei-Xing, Lin Richard Z, Bien Harold

Abstract excerpt

Constitutively active KRAS mutations are highly prevalent in lung cancers, but the direct role of its downstream phosphatidylinositol 3-kinase (PI3K) pathway in tumor progression remains unclear. A previous study established the requirement for PIK3CA, the alpha catalytic isoform, in lung tumor development in mouse models with an intact Trp53 tumor suppressor. In this study, we further investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinases

Share to Class I Phosphatidylinositol 3-Kinases

Share to Disease Progression

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41892297
DOI: 10.3390/cells15060506
PMCID: PMC13025534

Genes

PIK3CA
KRAS
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of PIK3CA Allows In Vitro Growth but Not In Vivo Progression of KRAS Mutant Lung Adenocarcinoma in a Syngeneic Orthotopic Implantation Model.PMID 41892297Read ↗

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read ↗

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung TumorigenesisSemantic proximity Read ↗

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.Semantic proximity Read ↗

Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo.Semantic proximity Read ↗

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047RSemantic proximity Read ↗

Non-conserved metabolic regulation by LKB1 distinguishes human and mouse lung adenocarcinomaSemantic proximity Read ↗

Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.Semantic proximity Read ↗

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinaseSemantic proximity Read ↗

LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma.Semantic proximity Read ↗

Concurrent <i>PIK3CA</i> mutant drives cachexia through inflammatory signaling in <i>EGFR</i> mutant lung cancerSemantic proximity Read ↗

Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.Semantic proximity Read ↗

Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.